In the BioHarmony Drug Report Database
Gemfibrozil
Lopid (gemfibrozil) is a small molecule pharmaceutical. Gemfibrozil was first approved as Lopid on 1982-01-01. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. The pharmaceutical is active against peroxisome proliferator-activated receptor alpha. In addition, it is known to target solute carrier organic anion transporter family member 2B1, solute carrier organic anion transporter family member 1B1, solute carrier organic anion transporter family member 1B3, and transthyretin.
Trade Name
|
Lopid |
|---|---|
Common Name
|
gemfibrozil |
ChEMBL ID
|
CHEMBL457 |
Indication
|
coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, hypertriglyceridemia |
Drug Class
|
Image (chem structure or protein)